Deferiprone
From Wikipedia, the free encyclopedia
 |
|
|
Deferiprone
|
|
| Systematic (IUPAC) name | |
| 3-hydroxy-1,2-dimethylpyridin-4(1H)-one | |
| Identifiers | |
| CAS number | |
| ATC code | V03 |
| PubChem | |
| Chemical data | |
| Formula | C7H9NO2 |
| Mol. mass | 139.152 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Glucuronidation |
| Half life | 2 to 3 hours |
| Excretion | Renal (75 to 90% in 24 hours) |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Deferiprone (tradenames include Ferriprox) is an oral drug that chelates iron and is used to treat thalassaemia major.[1]
It is currently licenced for use in the Europe and Asia, but not in Canada and the United States.[1]
[edit] Controversy
Deferiprone was at the centre of a protracted struggle between Nancy Olivieri, a Canadian haematologist and researcher, and the Hospital for Sick Children and pharmaceutical giant Apotex, that started in 1996.[2] Dr. Olivieri's data suggested that deferiprone leads to progressive hepatic fibrosis, a finding which is in dispute.[3][4]
[edit] References
- ^ a b Savulescu J (2004). "Thalassaemia major: the murky story of deferiprone". BMJ 328 (7436): 358–9. doi:. PMID 14962851. Full Text.
- ^ Viens A, Savulescu J (2004). "Introduction to The Olivieri symposium.". J Med Ethics 30 (1): 1–7. doi:. PMID 14872065. Free Full Text.
- ^ Brittenham G, Nathan D, Olivieri N, Porter J, Pippard M, Vichinsky E, Weatherall D (2003). "Deferiprone and hepatic fibrosis". Blood 101 (12): 5089–90; author reply 5090–1. doi:. PMID 12788794. Full Text.
- ^ Wanless I, Sweeney G, Dhillon A, Guido M, Piga A, Galanello R, Gamberini M, Schwartz E, Cohen A (2002). "Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia". Blood 100 (5): 1566–9. doi:. PMID 12176871. Full Text.
[edit] See also
|
||||||||
